Related Experiment Videos
Targeted drugs in concert with chemo: opposites attract
Clemens-Martin Wendtner1, Kirsten Fischer2
1KLINIKUM SCHWABING; UNIVERSITY OF COLOGNE.
Blood
|May 9, 2015
Abstract:
In this issue of Blood, Brown and colleagues show an impressive additional value when combining a tyrosine kinase inhibitor, that is, the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, with classic chemoimmunotherapy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma